Capital Flow Monitor · Sponsors · CIK 1783735
Delfi Diagnostics, Inc.
1810 Embarcadero Road, Palo Alto, CA, 94303 · 410-961-9015
Biotechnology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$60.0M
Sold
$34.3M
% sold
57.2%
Investors
50
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-12-18 | D ·current | 506(b) | $60.0M | $34.3M | 57.2% | 50 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Susan Tousi — Executive Officer / Director, Palo Alto, CA
- Peter B. Bach — Executive Officer, Palo Alto, CA
- Amoolya Singh — Executive Officer, Palo Alto, CA
- Lee-Ann Smith-Freeman — Executive Officer, Palo Alto, CA
- Victor Velculescu — Director, Palo Alto, CA
-
Greg Yap — Director, Palo Alto, CA
1 other raise
- Cartwheel Care Inc. $35.2M of $44.0M · 79.9%
-
Rishi Gupta — Director, Palo Alto, CA
3 other raises
- Wilshire Selective Opportunities Program SPC - WilSOP Segregated Portfolio 5 $30.0M of —
- Golden Teak Capital L.P. $800K of —
- CHARM Therapeutics Inc. $17.3M of $80.1M · 21.6%
-
Michael Dybbs — Director, Palo Alto, CA
3 other raises
- Abcuro, Inc. $39.4M of $176.5M · 22.3%
- Claris Biotherapeutics, Inc. $55.7M of $121.5M · 45.9%
- Samsara Opportunity Fund, L.P. $98.0M of $200.0M · 49.0%
- Elizabeth Homans — Director, Palo Alto, CA
- Justin Kao — Director, Palo Alto, CA
- Jacob Van Naarden — Director, Palo Alto, CA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.